IPA Quote, Financials, Valuation and Earnings

MAIA Biotechnology has a net margin of -349.88% compared to ImmunoPrecise Antibodies's net margin of --. ImmunoPrecise Antibodies's return on equity of -132.89% beat MAIA Biotechnology's return on equity of --.

ImmunoPrecise Antibodies has a consensus price target of $4.0000, signalling upside risk potential of 129.89%. On the other hand MAIA Biotechnology has an analysts' consensus of $12.14 which suggests that it could grow by 581.74%. Given that MAIA Biotechnology has higher upside potential than ImmunoPrecise Antibodies, analysts believe MAIA Biotechnology is more attractive than ImmunoPrecise Antibodies.

ImmunoPrecise Antibodies has a beta of 0.458, which suggesting that the stock is 54.193% less volatile than S&P 500. In comparison MAIA Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ImmunoPrecise Antibodies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MAIA Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunoPrecise Antibodies pays -- of its earnings as a dividend. MAIA Biotechnology pays out -- of its earnings as a dividend.

ImmunoPrecise Antibodies quarterly revenues are $4.3M, which are larger than MAIA Biotechnology quarterly revenues of --. ImmunoPrecise Antibodies's net income of -$15.1M is lower than MAIA Biotechnology's net income of -$4.5M. Notably, ImmunoPrecise Antibodies's price-to-earnings ratio is -- while MAIA Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunoPrecise Antibodies is 2.87x versus -- for MAIA Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -349.88% compared to ImmunoPrecise Antibodies's net margin of -49.65%. ImmunoPrecise Antibodies's return on equity of -132.89% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ImmunoPrecise Antibodies has a consensus price target of $4.0000, signalling upside risk potential of 129.89%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that ImmunoPrecise Antibodies has higher upside potential than NovaBay Pharmaceuticals, analysts believe ImmunoPrecise Antibodies is more attractive than NovaBay Pharmaceuticals.

ImmunoPrecise Antibodies has a beta of 0.458, which suggesting that the stock is 54.193% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

ImmunoPrecise Antibodies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunoPrecise Antibodies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ImmunoPrecise Antibodies quarterly revenues are $4.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ImmunoPrecise Antibodies's net income of -$15.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, ImmunoPrecise Antibodies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunoPrecise Antibodies is 2.87x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -349.88% compared to ImmunoPrecise Antibodies's net margin of --. ImmunoPrecise Antibodies's return on equity of -132.89% beat Oragenics's return on equity of --.

ImmunoPrecise Antibodies has a consensus price target of $4.0000, signalling upside risk potential of 129.89%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than ImmunoPrecise Antibodies, analysts believe Oragenics is more attractive than ImmunoPrecise Antibodies.

ImmunoPrecise Antibodies has a beta of 0.458, which suggesting that the stock is 54.193% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

ImmunoPrecise Antibodies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunoPrecise Antibodies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

ImmunoPrecise Antibodies quarterly revenues are $4.3M, which are larger than Oragenics quarterly revenues of --. ImmunoPrecise Antibodies's net income of -$15.1M is lower than Oragenics's net income of -$2.2M. Notably, ImmunoPrecise Antibodies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunoPrecise Antibodies is 2.87x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -349.88% compared to ImmunoPrecise Antibodies's net margin of --. ImmunoPrecise Antibodies's return on equity of -132.89% beat Theriva Biologics's return on equity of --.

ImmunoPrecise Antibodies has a consensus price target of $4.0000, signalling upside risk potential of 129.89%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than ImmunoPrecise Antibodies, analysts believe Theriva Biologics is more attractive than ImmunoPrecise Antibodies.

ImmunoPrecise Antibodies has a beta of 0.458, which suggesting that the stock is 54.193% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

ImmunoPrecise Antibodies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunoPrecise Antibodies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

ImmunoPrecise Antibodies quarterly revenues are $4.3M, which are larger than Theriva Biologics quarterly revenues of --. ImmunoPrecise Antibodies's net income of -$15.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, ImmunoPrecise Antibodies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunoPrecise Antibodies is 2.87x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.